

Thalassemia Market Size, Share & Trends Analysis Report By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (U.S., U.K., France, Germany, Italy, Spain, Japan), And Segment Forecasts, 2016 - 2022

<https://marketpublishers.com/r/T595EB7871FEN.html>

Date: March 2018

Pages: 71

Price: US\$ 5,950.00 (Single User License)

ID: T595EB7871FEN

Abstracts

This report can be delivered to the clients within 48 Hours

The global thalassemia market size is expected to be valued at USD 3.53 billion by 2022, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 10.8% during the forecast period. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in U.S.

Increase in incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across

different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Further key findings from the report suggest:

The global thalassemia market is expected to expand at a lucrative CAGR of 10.8% over the forecast period because of improved safety and efficacy profiles of gene therapy

India and Thailand are expected to offer lucrative growth opportunities for market expansion

Some of the key players in the industry with promising pipeline products are bluebird bio, Inc.; Acceleron Pharma; Novartis AG; Incyte Corporation; Kiadis Pharma; Gamida Cell; and Celgene Corporation

Blood transfusion and iron chelation therapies were the preferred treatment options for thalassemia in 2016, owing to their higher usage, ease, and affordability. However, the segments are likely to lose market share over the forecast period due to increase in adoption of curative gene therapy

Regionally, among the seven major markets, EU5 held the dominant share in terms of revenue in 2016, followed by U.S. and Japan

U.S. is expected to be the fastest growing region with a lucrative CAGR from 2016 to 2022 due to increase in prevalence of the disease and presence of well-established healthcare services

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 RESEARCH METHODOLOGY

- 2.1 Information Procurement
- 2.2 Information or Data Analysis
- 2.3 Market Formulation & Validation

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1 1 Chapter Summary
 - 3.1.1 Disease Primer
 - 3.1.2 Epidemiology by Indications
 - 3.1.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)

CHAPTER 4 GLOBAL MARKET OVERVIEW

- 4.1 1 Chapter Summary
 - 4.1.1 Introduction and market overview
 - 4.1.2 Market by therapeutic class
 - 4.1.3 Market by treatments
 - 4.1.4 Market size and forecast
 - 4.1.5 Market share distribution for seven major markets (U.S., Japan, and EU5)
 - 4.1.6 Market dynamics among leading brands
- 4.2 Patent Expiry Analysis
- 4.3 Drivers & Challenges
 - 4.3.1 Drivers
 - 4.3.2 Challenges
- 4.4 M&A, Deal Landscape (2013 - 2017 YTD)
- 4.5 Emerging Markets
- 4.6 Therapeutic Sector SWOT

CHAPTER 5 PRODUCT PIPELINE

- 5.1 Pipeline Landscape
 - 5.1.1 Leading drugs in development (Chart summary)
 - 5.1.2 Key R&D trends (New targets & MoA)

- 5.2 Promising Drug Candidates in Pipeline
 - 5.2.1 Late-stage pipeline analysis
 - 5.2.2 Profiles of the disruptive drugs/revolutionary treatments
- 5.3 Global Pipeline Forecast

CHAPTER 6 COMPETITIVE LANDSCAPE

- 6.1 Bluebird Bio
 - 6.1.1 Company Overview
 - 6.1.2 Current Product Portfolio - Major Products
 - 6.1.3 Product Forecast Sales through 2022
 - 6.1.4 Strategic Initiatives
 - 6.1.5 Key Company News flow
 - 6.1.6 Pipeline View
 - 6.1.7 Catalysts & Events Calendar
 - 6.1.8 SWOT Analysis
- 6.2 Novartis
 - 6.2.1 Company Overview
 - 6.2.2 Current Product Portfolio - Major Products
 - 6.2.3 Product Forecast Sales through 2022
 - 6.2.4 Strategic Initiatives
 - 6.2.5 Key Company News Flow
 - 6.2.6 Pipeline View
 - 6.2.7 Catalysts & Events Calendar
 - 6.2.8 SWOT Analysis
- 6.3 Kiadis Pharma
 - 6.3.1 Company Overview
 - 6.3.2 Current Product Portfolio - Major Products
 - 6.3.3 Product Forecast Sales Through 2022
 - 6.3.4 Strategic Initiatives
 - 6.3.5 Key Company News Flow
 - 6.3.6 Pipeline View
 - 6.3.7 SWOT Analysis
- 6.4 Acceleron Pharma / Celgene Corporation
 - 6.4.1 Company Overview
 - 6.4.2 Current Product Portfolio - Major Products
 - 6.4.3 Strategic Initiatives
 - 6.4.4 Key Company News Flow
 - 6.4.5 Pipeline View

6.4.6 Catalysts & Events Calendar

6.4.7 SWOT Analysis

CHAPTER 7 MARKET OUTLOOK

7.1 What the Future Holds

7.2 The Winner and Losers

7.3 Emerging Companies/New Technology Platforms

7.4 The Road Ahead

List Of Tables

LIST OF TABLES

Table 1 Current Prevalence Rates and Numbers for Seven Major Markets - 2016

Table 2 Global Thalassemia Market Share Distribution (2016 - 2022)

Table 3 U.S. Patents for Current Thalassemia Drugs

Table 4 R&D Pipeline Overview

Table 5 Late Stage Pipeline

Table 6 Disruptive Drug : Lentiglobin

Table 7 Disruptive Drug : Luspatercept

Table 8 Pipeline Forecast

Table 9 Sales Forecast through 2022 (in \$ Million)

Table 10 Bluebird bio. Pipeline View

Table 11 Bluebird bio. Events Calendar

Table 12 Sales Forecast, 2016 - 2022 (in \$ Million)

Table 13 Novartis Pipeline View

Table 14 Novartis Events Calendar

Table 15 Kiadis Pharma Pipeline View

Table 16 Acceleron Pharma Pipeline View

Table 17 Acceleron Pharma Events Calendar

List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value chain based sizing & forecasting
- Fig. 6 QFD modelling for market share assessment
- Fig. 7 Current prevalence rates for 7 major markets - 2016
- Fig. 8 Current prevalence numbers for 7 major markets - 2016
- Fig. 9 Global thalassemia market forecast (2016 - 2022)
- Fig. 10 Global thalassemia market share distribution (2016 - 2022)
- Fig. 11 Market share distribution for seven major markets (U.S., Japan, and EU5)
- Fig. 12 SWOT analysis (Global thalassemia market)
- Fig. 13 Bluebird bio. Pipeline view
- Fig. 14 SWOT analysis (Bluebird bio)
- Fig. 15 SWOT analysis (Novartis)
- Fig. 16 SWOT analysis (Kiadis Pharma)
- Fig. 17 Acceleron pharma pipeline view
- Fig. 18 SWOT analysis (Acceleron Pharma/Celgene Corporation)

I would like to order

Product name: Thalassemia Market Size, Share & Trends Analysis Report By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (U.S., U.K., France, Germany, Italy, Spain, Japan), And Segment Forecasts, 2016 - 2022

Product link: <https://marketpublishers.com/r/T595EB7871FEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T595EB7871FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970